Hypoxia-inducible factor-1a (HIF-1a) is destabilized via the ubiquitin-proteasome system. Thus HIF-1a expression is robustly upregulated by proteasome inhibition, but paradoxically its activity is reduced. In the present study, we investigated the mechanism underlying the paradoxical response of HIF-1a to proteasome inhibition. In both Hep3B and HEK293 cells, a proteasome inhibitor MG132 noticeably attenuated hypoxic induction of erythropoietin and VEGF mRNAs. MG132 inactivated HIF-1a C-terminal transactivation domain (CAD), independently of factor inhibiting HIF-1 (FIH) and inhibited p300 recruitment by HIF-1a. We next tested the possibility that CITED2 is involved in the HIF-1 inactivation. CITED2 was found to be degraded via the ubiquitin-proteasome system and thus was stabilized by proteasome inhibition. Both the activity and the p300 binding of HIF-1a were inhibited by CITED2 expression and recovered by CITED2 siRNA in the presence of MG132. These results suggest that CITED2 is stabilized by proteasome inhibition and inactivates HIF-1 by interfering with the HIF-1a-p300 interaction. This may be an important mode-of-action for proteasome inhibition-based cancer therapy.
Tumor cells can survive in hypoxic microenvironments by expressing a variety of proteins via hypoxia-inducible factor-1 (HIF-1) (Harris, 2002) . HIF-1 is a transcription factor composed of HIF-1a, the primary transactivating factor and aryl hydrocarbon receptor nuclear translocator (ARNT/HIF-1b). Under normoxic conditions, HIF-1-prolyl hydroxylases (PHD1-3) hydroxylate P402 and P564 of HIF-1a, which leads to von Hippel-Lindau protein-mediated ubiquitination and proteasomal degradation of HIF-1a (Schofield and Ratcliffe, 2004) . In addition, HIF-1a is functionally regulated by factor inhibiting HIF-1 (FIH). FIH hydroxylates N803 in the transactivation domain and inhibits p300/CBP recruitment, repressing HIF-1 activity (Lando et al., 2002) . In contrast, under hypoxic conditions, both hydroxylation processes are inhibited, and HIF-1a is stabilized and activated.
Since ubiquitin-proteasome system (UPS)-dependent turnover of proteins in cancer cells differs from that in normal cells, proteasome inhibition is viewed as a new anticancer strategy (Adams, 2004) . HIF-1a, a positive player in tumor promotion, is also included in UPS targets. However, in spite of HIF-1a accumulation, proteasome inhibition paradoxically inactivated HIF-1 (Kallio et al., 1999; Kaluz et al., 2006) . Birle and Hedley (2007) also demonstrated that HIF-1a in xenografted tumors was increased by bortezomib proteasome inhibitor; in contrast, carbonic anhydrase IX and vascular endothelial growth factor (VEGF), both of which are upregulated by HIF-1, were downregulated. Under normoxic conditions, HIF-1a induced by proteasome inhibition can be non-functional because FIH inactivates HIF-1a. However, why is HIF-1a inactivated by proteasome inhibition under hypoxic conditions? Since FIH is inactive under hypoxic conditions, cellular processes other than the asparagine hydroxylation may be involved in HIF-1 inactivation by proteasome inhibition. In the present study, we aimed to investigate this question.
First, we checked erythropoietin (EPO) and VEGF mRNAs in Hep3B hepatoma cells. As expected, both mRNA levels increased under hypoxic conditions, but were reduced by MG132 proteasome inhibitor ( Figure 1a) . In reporter assays, MG132 inhibited both EPO enhancer and VEGF promoter activities in Hep3B (Figure 1b ) or HEK293 human embryonic kidney cells (Supplementary Figure 1) . To analyse the transcriptional activity of HIF-1, we co-transfected HEK293 cells with Gal4-HIF-1a C-terminal trans-activation domain (CAD) and Gal4-Luc reporter plasmids. CAD was activated under hypoxic conditions and this activation was attenuated by MG132 ( Figure 1c) . We also analysed the activity of Gal4-CAD N803A mutant and found that it was constitutively active regardless of oxygen tension because it is not regulated by FIH. Interestingly, MG132 also inhibited CAD N803A activity (Figure 1c) , suggesting that CAD inactivation by proteasome inhibition is independent of FIH. Since p300 binding is essential for HIF-1 activation (Arany et al., 1996) , we also examined the interaction between CAD and p300 using a mammalian two-hybrid assay, in which reporter activity was assessed by this interaction. Figure 1d shows that the CAD-p300 interaction was enhanced by hypoxia and that this interaction was attenuated by MG132 in both Hep3B and HEK293 cells. In addition, another proteasome inhibitor, bortezomib also inhibited EPO and VEGF expression by repressing CAD activity (Supplementary Figure 2) . These results suggest that proteasome inhibition prevents p300 recruitment by HIF-1a and thus inactivates HIF-1 in FIH-independent fashion.
How is the HIF-1a-p300 interaction blocked by proteasome inhibition? Previously, Kaluz et al. (2006) suggested the possible involvement of STAT2 in HIF-1 repression by proteasome inhibition. However, VEGF suppression by MG132 was not recovered by knockingdown STAT2 (Supplementary Figure 3) , indicating that STAT2 is not responsible for HIF-1 repression. As the next candidate, we considered CBP/p300 interacting transactivator with ED-rich tail 2 (CITED2 also known as Mrg1 or p35srj), because it has been reported to interfere with this interaction (Shioda et al., 1996; Dunwoodie et al., 1998; Sun et al., 1998) . CITED2 associates with p300 CH1 domain, and modulates the activities of p300-dependent transcription factors. For example, CITED2 activates AP-2 by enhancing p300 recruitment (Braganca et al., 2003) , but inactivates HIF-1. 32 P]dCTP, and electrophoresed on a 4% polyacrylamide gel, and autoradiographed. Primers were designed as previously described (Chun et al., 2002) . (b) Luciferase plasmid (0.5 mg) containing erythropoietin (EPO) enhancer or vascular endothelial growth factor (VEGF) promoter was co-transfected with 0.5 mg of b-gal plasmid into Hep3B cells (Yeo et al., 2006) . After 16 h incubation, luciferase activities were measured using a Biocounter M1500 luminometer (Lumac) and were normalized to b-gal activity. Results (means±s.d, n ¼ 8) are presented as relative values vs the normoxic control. w Po0.05 vs the normoxic controls; *Po0.05 vs the hypoxic controls. (c) Gal4-CAD (aa. 776-826) (WT) or Gal4-CAD N803A plasmid (1 mg) was co-transfected with Gal4-luc reporter plasmid (1 mg) into HEK293 cells (Yeo et al., 2006) . Results (means ± s.d, n ¼ 8) are presented as relative values vs the normoxic control of Gal4-CAD(WT) reporter. (d) For mammalian two-hybrid assay of HIF-1a CAD-p300 binding, Hep3B or HEK293 cells were co-transfected with 1 mg of Gal4-luciferase reporter, 1 mg of pGal4-CAD, and 0.5 mg of pVP16-p300 CH1 (Yeo et al., 2006) . Results (means ± s.d, n ¼ 4) are presented as relative values vs the normoxic controls.
w Po0.05 vs the normoxic controls; *Po0.05 vs the hypoxic controls.
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DH Shin et al HIF-1a and CITED2 commonly bind with p300 CH1, but CITED2 has a 33-fold higher affinity than HIF-1a. Thus, CITED2 dissociates p300 from HIF-1a and represses HIF-1a activity (Freedman et al., 2003) . The negative role of CITED2 in HIF-1 activation has been also supported in vivo (Yin et al., 2002; Xu et al., 2007) . In the present study, we tested whether CITED2 is involved in HIF-1 inactivation by proteasome inhibition. In Figure 2a , HIF1a was upregulated by MG132 under both normoxic and hypoxic conditions. Interestingly, CITED2 levels were also markedly increased by MG132. The CITED2 induction by MG132 was also observed in other cancer cell lines, HT1080 fibrosarcoma and H1299 non-small cell lung cancer (Figure 2b ). The specificity of CITED2 antibody was verified using siRNA. When de novo protein synthesis was blocked using cycloheximide, CITED2 disappeared within 60 min, but in the presence of MG132, a substantial amount of CITED2 remained until 240 min (Figure 2c) . Also, ubiquitinated forms were identified in immunoprecipitated CITED2 (Figure 2d ), but not in b-tubulin (Supplementary Figure 4) . These results suggest that CITED2 is degraded via UPS and thus is stabilized by proteasome inhibition.
To examine whether CITED2 stabilization is responsible for FIH-independent inactivation of HIF-1, we transfected cells with the CITED2 plasmid or siRNA and measured the activity of CAD N803A. CITED2 expression and knockdown were confirmed by western blotting (Supplementary Figure 5) . In both Hep3B and HEK293 cells, CAD N803A activity was inhibited by CITED2 expression, and CITED2 siRNA significantly rescued the CAD N803A activity repressed by MG132 (Figure 3a) . Moreover, mammalian two-hybrid ( Figure 3b ) and co-immunoprecipitation (Figure 3c ) assays show that CITED2 knockdown recovered the HIF-1a-p300 interaction inhibited by MG132. In chromatin immunoprecipitation analysis, p300 recruitment on the EPO and VEGF genes was inhibited by MG132 and was recovered by knocking-down CITED2 in Hep3B (Figure 3d) . In mRNA levels, the hypoxic induction of EPO or VEGF was inhibited by CITED2 expression and MG132, and was fully recovered by knocking-down CITED2 in Hep3B (Figure 4a ), HT1080 ( Figure 4b ) and H1299 (Figure 4b ) cells. These results suggest that CITED2 is stabilized by proteasome inhibition, interferes with HIF-1a-p300 interaction 
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and inactivates HIF-1, thereby suppressing the expression of genes essential for cellular adaptation to hypoxia. This mechanism is summarized in Figure 4c .
CITED2 expression is regulated transcriptionally. The human CITED2 promoter contains three HIF-1 binding elements, and thus its transcription is induced under hypoxic conditions (Bhattacharya et al., 1999) . Then, the expressed CITED2 inversely inhibits hypoxic gene regulation by inactivating HIF-1. CITED2 is also regulated post-transcriptionally. For instance, CITED2 mRNA instability is mediated via the Smad pathway during TGF-b stimulation (Chou and Yang, 2006) . In addition, CITED2 expression can be regulated post-translationally. Previously, CITED2 was reported to be an unstable protein with a half-life of about 20 min (Bhattacharya et al., 1999) . More than likely, as in the present study, most CITED2 was degraded within 60 min after cycloheximide treatment. Moreover, we identified that the proteolytic turnover of CITED2 was mediated by UPS (Figure 2) . The fast turnover of CITED2 is important in the hypoxic activation of HIF-1 in the early stage of hypoxia. The lower steady-state level of CITED2 leaves p300 unoccupied, which provides for p300 recruitment by HIF-1a (Bhattacharya et al., 1999) . However, when CITED2 accumulates following proteasome inhibition, it can occupy most p300/CBP with a higher affinity Figure 3 CBP/p300 interacting transactivator with ED-rich tail 2 (CITED2) is responsible for hypoxia-inducible factor-1 (HIF-1) inactivation and blockade of p300 recruitment during proteasome inhibition. CITED2 cDNA was cloned by reverse transcriptasepolymerase chain reaction using PFU DNA polymerase, and inserted into pcDNA. (a) CITED2 plasmid (1, 2, 3 mg) or siRNA (80 nM) was co-transfected with Gal4-CAD N803A plasmid (1 mg) and Gal4-luc reporter plasmid (1 mg) into Hep3B or HEK293. Control siRNA (siCon) sequence was 5 0 -CAAGACCCGCGCCGAGGUGAAUU-3 0 . The cells were incubated under indicated conditions for 16 h or with 10 mM MG132. Results (means±s.d, n ¼ 4) are presented as relative luciferase activities vs the normoxic controls. (b) The interaction between HIF-1a and p300 was checked using the mammalian two-hybrid assay. The CITED2 plasmid (3 mg) or siRNA (80 nM) was co-transfected with 1 mg of Gal4-luciferase reporter, 1 mg of pGal4-CAD, and 0.5 mg of pVP16-p300 CH1 into Hep3B cells. Results (means ± s.d, n ¼ 6) are presented as relative luciferase activities vs the normoxic controls. *Po0.05 vs the hypoxic controls; #Po0.05 vs the siCon groups. (c) p300 binding to HIF-1a was examined using the co-immunoprecipitation assay. HEK293 cells were co-transfected with HIF-1a (2 mg) and p300 (1 mg) plasmids, and incubated under indicated conditions for 8 h. p300 was immunoprecipitated with anti-p300 antibody and protein G/A beads (IP), and co-precipitated HIF-1a was identified by western blotting (WB). (d) p300 recruitment by HIF-1a was analysed by chromatin immunoprecipitation. Fixed chromatin samples were precipitated with anti-p300 antiserum, and precipitated DNAs were amplified by PCR with [a- 
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DH Shin et al than HIF-1a, which results in HIF-1 inactivation even under hypoxic conditions. In many respects, HIF-1 is viewed as a tumor marker for poor prognosis. In addition to its promotion of angiogenesis and hypoxic adaptation, HIF-1 induces the expression of genes associated with tumor spreading and resistance to radio/chemotherapy (Liao et al., 2007; Sasabe et al., 2007) . Moreover, HIF-1 promotes genetic alterations by inactivating DNA mismatch repair enzymes, which may contribute to the progression of more malignant tumor phenotypes in hypoxic microenvironments (Koshiji et al., 2005) . Therefore, CITED2-mediated inactivation of HIF-1 might be an important mode-of-action in proteasome inhibitionbased cancer therapy. However, since a variety of proteins are also upregulated by proteasome inhibition, it is uncertain how much CITED2 induction will contribute to the cancer therapy. 
CITED2
Figure 4 CBP/p300 interacting transactivator with ED-rich tail 2 (CITED2) is responsible for hypoxia-inducible factor-1 (HIF-1) target gene repression by proteasome inhibition. Erythropoietin (EPO) or vascular endothelial growth factor (VEGF) mRNA levels in Hep3B cells (a) or HT1080 and H1299 cells (b) were analysed. Assay procedures and experimental conditions are same as described in Figure 1a and Figure 3a . (c) Mechanism underlying HIF-1a repression by proteasome inhibition. When proteasome is inhibited, CITED2 is accumulated and dissociates p300 from HIF-1a, thus repressing the transcriptional activity of HIF-1.
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